<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7280997\results\search\disease\results.xml">
  <result pre=": italic;} PathogensPathogenspathogensPathogens2076-0817MDPI doi: 10.3390/pathogens9050331pathogens-09-00331 : Review The Human Coronavirus" exact="Disease" post="COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs"/>
  <result pre="Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The emerging coronavirus" exact="disease" post="(COVID-19) swept across the world, affecting more than 200"/>
  <result pre="virus originated in bats and transmitted to humans through unknown" exact="intermediate" post="hosts in the Wuhan seafood market, China, in December"/>
  <result pre="the Betacoronavirus group, the same group of the 2003 severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), and for the similarity, it"/>
  <result pre="Betacoronavirus group, the same group of the 2003 severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), and for the similarity, it was"/>
  <result pre="group, the same group of the 2003 severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), and for the similarity, it was named"/>
  <result pre="COVID-19 treatment. COVID-19 SARS-CoV-2 antiviral therapies 1. Introduction The coronavirus" exact="disease" post="2019 (COVID-19) was first identified in patients with severe"/>
  <result pre="disease 2019 (COVID-19) was first identified in patients with severe" exact="respiratory" post="disease in Wuhan, China. The causative agent was a"/>
  <result pre="2019 (COVID-19) was first identified in patients with severe respiratory" exact="disease" post="in Wuhan, China. The causative agent was a novel"/>
  <result pre="The causative agent was a novel coronavirus scientifically named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2]. Since its discovery,"/>
  <result pre="causative agent was a novel coronavirus scientifically named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [1,2]. Since its discovery, more"/>
  <result pre="agent was a novel coronavirus scientifically named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [1,2]. Since its discovery, more than"/>
  <result pre="ability to spread readily and its propensity to cause severe" exact="disease" post="in older adults and patients with existing health conditions"/>
  <result pre="or vaccines available for COVID-19. Treatments are mainly focusing on" exact="symptomatic" post="and respiratory support according to protocols issued by the"/>
  <result pre="available for COVID-19. Treatments are mainly focusing on symptomatic and" exact="respiratory" post="support according to protocols issued by the health authority"/>
  <result pre="a viable vaccine for SARS-CoV-2. However, this is not a" exact="short" post="process; scientists estimate the period to have one, about"/>
  <result pre="cause a large-scale epidemic in the twenty-first century after the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 [8,9,10] and"/>
  <result pre="a large-scale epidemic in the twenty-first century after the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 [8,9,10] and the"/>
  <result pre="large-scale epidemic in the twenty-first century after the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus (SARS-CoV) in 2003 [8,9,10] and the Middle"/>
  <result pre="epidemic in the twenty-first century after the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus (SARS-CoV) in 2003 [8,9,10] and the Middle East"/>
  <result pre="Syndrome Coronavirus (SARS-CoV) in 2003 [8,9,10] and the Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) in 2012 [11,12,13]. Our knowledge and"/>
  <result pre="Coronavirus (SARS-CoV) in 2003 [8,9,10] and the Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) in 2012 [11,12,13]. Our knowledge and experience"/>
  <result pre="and azithromycin [14]. Furthermore, the antiviral drug remdesivir and the" exact="malaria" post="drug chloroquine have gained much attention globally as potential"/>
  <result pre="each treatment strategy could act on preventing or slowing the" exact="viral infection." post="2. Coronaviruses Coronaviruses (CoVs) are a large group of"/>
  <result pre="viruses common among many animals, including humans. They can cause" exact="respiratory" post="illnesses in humans and gastrointestinal illnesses in animals. Under"/>
  <result pre="causing mild symptoms in immunocompetent people. Typically, coronavirus symptoms include" exact="runny nose," post="cough, sore throat, headache, and fever that can last"/>
  <result pre="there is a chance that the virus could cause a" exact="lower" post="respiratory illness like pneumonia and bronchitis [16,17]. In 2003,"/>
  <result pre="is a chance that the virus could cause a lower" exact="respiratory" post="illness like pneumonia and bronchitis [16,17]. In 2003, the"/>
  <result pre="that the virus could cause a lower respiratory illness like" exact="pneumonia" post="and bronchitis [16,17]. In 2003, the world was shocked"/>
  <result pre="virus could cause a lower respiratory illness like pneumonia and" exact="bronchitis" post="[16,17]. In 2003, the world was shocked by the"/>
  <result pre="shocked by the first pandemic of the 21st century; the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus (SARS-CoV) emerged in Guangdong, China,"/>
  <result pre="by the first pandemic of the 21st century; the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus (SARS-CoV) emerged in Guangdong, China, resulting"/>
  <result pre="the first pandemic of the 21st century; the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus (SARS-CoV) emerged in Guangdong, China, resulting in"/>
  <result pre="first pandemic of the 21st century; the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus (SARS-CoV) emerged in Guangdong, China, resulting in 774"/>
  <result pre="CoV evolved in Saudi Arabia to cause the Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV), approximately 2500 cases have been confirmed,"/>
  <result pre="evolved in Saudi Arabia to cause the Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV), approximately 2500 cases have been confirmed, including"/>
  <result pre="the other hand, Alphacoronaviruses and Betacoronaviruses are capable of causing" exact="respiratory" post="illnesses in humans and gastrointestinal illnesses in animals. Before"/>
  <result pre="most cases, these viruses were transmitted to humans through an" exact="intermediate" post="animal host. SARS-CoV started through direct contact with market"/>
  <result pre="SARS-CoV-2 was originated in bats and transmitted to humans through" exact="intermediate" post="animal host in the seafood market [5]. Nevertheless, researchers"/>
  <result pre="find a definitive answer to which animal serves as an" exact="intermediate" post="host. 2.2. Coronavirus Genome Structure and Replication The CoVs"/>
  <result pre="HE protein, 3a/b protein, and 4a/b protein [24]. Once the" exact="viral" post="genome enters the cytoplasm of the target cell, and"/>
  <result pre="form of discontinuous transcription [24]. SARS-CoV-2 primarily infects ciliated bronchial" exact="epithelial" post="cells and type II pneumocytes, where it binds to"/>
  <result pre="transcription [24]. SARS-CoV-2 primarily infects ciliated bronchial epithelial cells and" exact="type II" post="pneumocytes, where it binds to the surface receptor, angiotensin-converting"/>
  <result pre="S1 determines the host range and cellular tropism and facilitates" exact="viral" post="attachment to the target cells. S2 is a unit"/>
  <result pre="cells. S2 is a unit that mediates the fusion of" exact="viral" post="and cellular membranes, ensuring viral entry through endocytosis. [31]."/>
  <result pre="that mediates the fusion of viral and cellular membranes, ensuring" exact="viral" post="entry through endocytosis. [31]. The affinity between the virusâ€™s"/>
  <result pre="surface proteins and its receptors is a critical step for" exact="viral" post="entry. Understanding the mechanism of SARS-CoV-2 could provide more"/>
  <result pre="the mechanism of SARS-CoV-2 could provide more insights into the" exact="viral" post="transmission and reveal therapeutic targets. A recent study showed"/>
  <result pre="higher than that of SARS-CoV, which could explain the highly" exact="infectious" post="ability of SARS-CoV-2 [4,34]. 3. Potential COVID-19 Treatment Antiviral"/>
  <result pre="3. Potential COVID-19 Treatment Antiviral drugs usually interfere with the" exact="viral" post="replication machinery in the target cells. Given that viruses"/>
  <result pre="making it the prioritized drug to treat malaria, viruses, and" exact="autoimmune" post="conditions [51]. There are several potential molecular mechanisms of"/>
  <result pre="TNF), thereby inhibiting various immune pathways that might lead to" exact="acute" post="respiratory distress syndrome (ARDS) [52]. Currently, the use of"/>
  <result pre="thereby inhibiting various immune pathways that might lead to acute" exact="respiratory" post="distress syndrome (ARDS) [52]. Currently, the use of hydroxychloroquine"/>
  <result pre="various immune pathways that might lead to acute respiratory distress" exact="syndrome" post="(ARDS) [52]. Currently, the use of hydroxychloroquine is approved"/>
  <result pre="other RNA viruses [53]. It acts through interfering with the" exact="viral" post="RNA polymerase and evades proofreading by viral exoribonuclease, leading"/>
  <result pre="interfering with the viral RNA polymerase and evades proofreading by" exact="viral" post="exoribonuclease, leading to a decrease in viral RNA production"/>
  <result pre="evades proofreading by viral exoribonuclease, leading to a decrease in" exact="viral" post="RNA production [54,55]. A recent report found that a"/>
  <result pre="II receptor antagonist group. They block the substances that cause" exact="blood vessels" post="narrowing, which lowers blood pressure and improves blood flow"/>
  <result pre="lowers blood pressure and improves blood flow by relaxing the" exact="blood vessels." post="It has been suggested that Losartan can be used"/>
  <result pre="Baricitinib is a drug used basically for the treatment of" exact="rheumatoid arthritis." post="It acts as an inhibitor for Janus kinase (JAK,"/>
  <result pre="recent study showed that combination of these drugs reduced SARS-CoV-2" exact="viral" post="load and improved the clinical symptoms during the treatment"/>
  <result pre="control group [44]. 3.7. Camostat Mesylate Camostat Mesylate is a" exact="type II" post="transmembrane serine protease (TMSPSS2) inhibitor [62]. Since that SARS-CoV-2"/>
  <result pre="anti-malarial, antiviral, and anti-inflammatory activities. Those drugs showed significantly decreased" exact="viral" post="RNA yield in treated cells, making them potential drugs"/>
  <result pre="in treated cells, making them potential drugs for treating COVID-19" exact="infections" post="[47]. 3.9. SARS-CoV-Specific Human Monoclonal Antibody (CR3022) Passive immunization"/>
  <result pre="drugs for treating COVID-19 infections [47]. 3.9. SARS-CoV-Specific Human Monoclonal" exact="Antibody" post="(CR3022) Passive immunization (PI) is a method to obtain"/>
  <result pre="(PI) is a method to obtain instant, short-term fortification against" exact="infectious" post="agents by introducing pathogen-specific antibodies to patients. These specific"/>
  <result pre="cellular receptor. It is extremely applicable in the case of" exact="viral" post="antigens that facilitate the attachment to the target receptors"/>
  <result pre="attachment to the target receptors [63]. After exposure to a" exact="viral infection," post="the body of the patient creates antibodies to fight"/>
  <result pre="in life-threatening situations [66]. 3.10. CRISPR/Cas13d System Clustered regularly interspaced" exact="short" post="palindromic repeats (CRISPR) is a family of repeated DNA"/>
  <result pre="bacteria and archaea. These fragments are molecular remaining of bacteriophages" exact="infections" post="and act as a defense mechanism to the prokaryotic"/>
  <result pre="is a powerful technique that has been derived from the" exact="bacterial" post="defense mechanism and implemented in gene editing of our"/>
  <result pre="worst scenarios are possible. Despite our knowledge of the SARS-CoV-2" exact="infectious" post="cycle, there is no clear strategy for COVID-19 patientsâ€™"/>
  <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
  <result pre="infected with 2019 novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 2.ZhouP.YangX.-L.WangX.G.HuB.ZhangL.ZhangW.SiR.H.ZhuY.LiB.HuangC.-L.et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="coronavirus of probable bat originNature202057927027332015507 3.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.et al.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaNew Engl. J. Med.202010.1056/NEJMoa200203232109013 4.GuoY.-R.CaoQ.-D.HongZ.-S.TanY.-Y.ChenS.-D.JinH.TanK.-S.WangD.-Y.YanY.The origin, transmission"/>
  <result pre="J. Med.202010.1056/NEJMoa200203232109013 4.GuoY.-R.CaoQ.-D.HongZ.-S.TanY.-Y.ChenS.-D.JinH.TanK.-S.WangD.-Y.YanY.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;An update on the statusMil. Med Res.2020711010.1186/s40779-020-00240-031928528"/>
  <result pre="systematic reviewJ. Med. Virol.20209247949010.1002/jmv.2570732052466 8.LeeN.HuiD.S.WuA.ChanP.K.S.CameronP.JoyntG.AhujaA.T.YungM.Y.LeungC.ToK.et al.A major outbreak of severe" exact="acute" post="respiratory syndrome in Hong KongNew Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 9.PeirisJ.LaiS.PoonL.L.GuanY.YamL.LimW.NichollsJ.M.YeeW.YanW.CheungM.et"/>
  <result pre="reviewJ. Med. Virol.20209247949010.1002/jmv.2570732052466 8.LeeN.HuiD.S.WuA.ChanP.K.S.CameronP.JoyntG.AhujaA.T.YungM.Y.LeungC.ToK.et al.A major outbreak of severe acute" exact="respiratory" post="syndrome in Hong KongNew Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 9.PeirisJ.LaiS.PoonL.L.GuanY.YamL.LimW.NichollsJ.M.YeeW.YanW.CheungM.et al.Coronavirus"/>
  <result pre="Med. Virol.20209247949010.1002/jmv.2570732052466 8.LeeN.HuiD.S.WuA.ChanP.K.S.CameronP.JoyntG.AhujaA.T.YungM.Y.LeungC.ToK.et al.A major outbreak of severe acute respiratory" exact="syndrome" post="in Hong KongNew Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 9.PeirisJ.LaiS.PoonL.L.GuanY.YamL.LimW.NichollsJ.M.YeeW.YanW.CheungM.et al.Coronavirus as"/>
  <result pre="J. Med.20033481986199410.1056/NEJMoa03068512682352 9.PeirisJ.LaiS.PoonL.L.GuanY.YamL.LimW.NichollsJ.M.YeeW.YanW.CheungM.et al.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet20033611319132510.1016/S0140-6736(03)13077-212711465 10.De WitE.Van DoremalenN.FalzaranoD.MunsterV.SARS and MERS: Recent insights"/>
  <result pre="Med.20033481986199410.1056/NEJMoa03068512682352 9.PeirisJ.LaiS.PoonL.L.GuanY.YamL.LimW.NichollsJ.M.YeeW.YanW.CheungM.et al.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet20033611319132510.1016/S0140-6736(03)13077-212711465 10.De WitE.Van DoremalenN.FalzaranoD.MunsterV.SARS and MERS: Recent insights into"/>
  <result pre="insights into emerging coronavirusesNat. Rev. Genet.20161452353410.1038/nrmicro.2016.81 11.AlagailiA.N.BrieseT.MishraN.KapoorV.SameroffS.C.De WitE.MunsterV.HensleyL.E.ZalmoutI.S.KapoorA.et al.Middle east" exact="respiratory" post="syndrome coronavirus infection in dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.01002-1424570370"/>
  <result pre="into emerging coronavirusesNat. Rev. Genet.20161452353410.1038/nrmicro.2016.81 11.AlagailiA.N.BrieseT.MishraN.KapoorV.SameroffS.C.De WitE.MunsterV.HensleyL.E.ZalmoutI.S.KapoorA.et al.Middle east respiratory" exact="syndrome" post="coronavirus infection in dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.01002-1424570370 12.MemishZ.A.MishraN.OlivalK.J.FagboS.KapoorV.EpsteinJ.H.AlHakeemR.DurosinlounA.Al"/>
  <result pre="coronavirusesNat. Rev. Genet.20161452353410.1038/nrmicro.2016.81 11.AlagailiA.N.BrieseT.MishraN.KapoorV.SameroffS.C.De WitE.MunsterV.HensleyL.E.ZalmoutI.S.KapoorA.et al.Middle east respiratory syndrome coronavirus" exact="infection" post="in dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.01002-1424570370 12.MemishZ.A.MishraN.OlivalK.J.FagboS.KapoorV.EpsteinJ.H.AlHakeemR.DurosinlounA.Al AsmariM.IslamA.et al.Middle"/>
  <result pre="in dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.01002-1424570370 12.MemishZ.A.MishraN.OlivalK.J.FagboS.KapoorV.EpsteinJ.H.AlHakeemR.DurosinlounA.Al AsmariM.IslamA.et al.Middle East" exact="respiratory" post="syndrome coronavirus in bats, Saudi ArabiaEmerg. Infect. Dis.2013191819182310.3201/eid1911.13117224206838 13.ZakiA.M.Van"/>
  <result pre="dromedary camels in Saudi ArabiamBio20145e00884-1410.1128/mBio.01002-1424570370 12.MemishZ.A.MishraN.OlivalK.J.FagboS.KapoorV.EpsteinJ.H.AlHakeemR.DurosinlounA.Al AsmariM.IslamA.et al.Middle East respiratory" exact="syndrome" post="coronavirus in bats, Saudi ArabiaEmerg. Infect. Dis.2013191819182310.3201/eid1911.13117224206838 13.ZakiA.M.Van BoheemenS.BestebroerT.OsterhausA.D.FouchierR.A.M.Isolation"/>
  <result pre="13.ZakiA.M.Van BoheemenS.BestebroerT.OsterhausA.D.FouchierR.A.M.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaNew Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 14.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and"/>
  <result pre="gammacoronavirus and deltacoronavirusJ. Virol.2012863995400810.1128/JVI.06540-1122278237 22.ItheteN.StoffbergS.CormanV.M.CottontailV.M.RichardsL.R.SchoemanC.DrostenC.DrexlerJ.F.PreiserW.Close relative of human middle east" exact="respiratory" post="syndrome coronavirus in Bat, South AfricaEmerg. Infect. Dis.2013191697169910.3201/eid1910.13094624050621 23.GuanY.ZhengB.J.HeY.Q.LiuX.L.ZhuangZ.X.CheungC.L.LuoS.W.LiP.H.ZhangL.J.ButtK.M.et"/>
  <result pre="and deltacoronavirusJ. Virol.2012863995400810.1128/JVI.06540-1122278237 22.ItheteN.StoffbergS.CormanV.M.CottontailV.M.RichardsL.R.SchoemanC.DrostenC.DrexlerJ.F.PreiserW.Close relative of human middle east respiratory" exact="syndrome" post="coronavirus in Bat, South AfricaEmerg. Infect. Dis.2013191697169910.3201/eid1910.13094624050621 23.GuanY.ZhengB.J.HeY.Q.LiuX.L.ZhuangZ.X.CheungC.L.LuoS.W.LiP.H.ZhangL.J.ButtK.M.et al.Isolation"/>
  <result pre="The Netherlands200666193292 26.DemoginesA.FarzanM.SawyerS.Evidence for ACE2-Utilizing Coronaviruses (CoVs) related to severe" exact="acute" post="respiratory syndrome CoV in BatsJ. Virol.2012866350635310.1128/JVI.00311-1222438550 27.NeumanB.KissG.KundingA.BhellaD.BakshM.F.ConnellyS.DroeseB.KlausJ.P.MakinoS.SawickiS.G.et al.A structural"/>
  <result pre="Netherlands200666193292 26.DemoginesA.FarzanM.SawyerS.Evidence for ACE2-Utilizing Coronaviruses (CoVs) related to severe acute" exact="respiratory" post="syndrome CoV in BatsJ. Virol.2012866350635310.1128/JVI.00311-1222438550 27.NeumanB.KissG.KundingA.BhellaD.BakshM.F.ConnellyS.DroeseB.KlausJ.P.MakinoS.SawickiS.G.et al.A structural analysis"/>
  <result pre="26.DemoginesA.FarzanM.SawyerS.Evidence for ACE2-Utilizing Coronaviruses (CoVs) related to severe acute respiratory" exact="syndrome" post="CoV in BatsJ. Virol.2012866350635310.1128/JVI.00311-1222438550 27.NeumanB.KissG.KundingA.BhellaD.BakshM.F.ConnellyS.DroeseB.KlausJ.P.MakinoS.SawickiS.G.et al.A structural analysis of"/>
  <result pre="protein in coronavirus assembly and morphologyJ. Struct. Boil.2010174112210.1016/j.jsb.2010.11.021 28.DeDiegoM.L.Ã�lvarezE.AlmazÃ¡nF.RejasM.T.LamirandeE.RobertsA.ShiehW.-J.ZakiS.R.SubbaraoK.EnjuanesL.A severe" exact="acute" post="respiratory syndrome coronavirus that lacks the E Gene is"/>
  <result pre="in coronavirus assembly and morphologyJ. Struct. Boil.2010174112210.1016/j.jsb.2010.11.021 28.DeDiegoM.L.Ã�lvarezE.AlmazÃ¡nF.RejasM.T.LamirandeE.RobertsA.ShiehW.-J.ZakiS.R.SubbaraoK.EnjuanesL.A severe acute" exact="respiratory" post="syndrome coronavirus that lacks the E Gene is attenuated"/>
  <result pre="coronavirus assembly and morphologyJ. Struct. Boil.2010174112210.1016/j.jsb.2010.11.021 28.DeDiegoM.L.Ã�lvarezE.AlmazÃ¡nF.RejasM.T.LamirandeE.RobertsA.ShiehW.-J.ZakiS.R.SubbaraoK.EnjuanesL.A severe acute respiratory" exact="syndrome" post="coronavirus that lacks the E Gene is attenuated in"/>
  <result pre="1282123 30.CuiL.WangH.JiY.YangJ.XuS.HuangX.WangZ.QinL.TienP.ZhouX.et al.The nucleocapsid protein of coronaviruses acts as a" exact="viral" post="suppressor of RNA silencing in mammalian cellsJ. Virol.2015899029904310.1128/JVI.01331-1526085159 31.HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.SchiergensT.S.HerrlerG.WuN.-H.NitscheA.et"/>
  <result pre="for the SARS coronavirusNature200342645045410.1038/nature0214514647384 33.QianZ.TravantyE.A.OkoL.EdeenK.BerglundA.WangJ.ItoY.HolmesK.V.MasonR.J.Innate immune response of human alveolar" exact="Type II" post="cells infected with severe acute respiratory syndromeâ€&quot;coronavirusAm. J. Respir."/>
  <result pre="response of human alveolar Type II cells infected with severe" exact="acute" post="respiratory syndromeâ€&quot;coronavirusAm. J. Respir. Cell Mol. Boil.20134874274810.1165/rcmb.2012-0339OC23418343 34.LetkoM.MarziA.MunsterV.Functional assessment"/>
  <result pre="of human alveolar Type II cells infected with severe acute" exact="respiratory" post="syndromeâ€&quot;coronavirusAm. J. Respir. Cell Mol. Boil.20134874274810.1165/rcmb.2012-0339OC23418343 34.LetkoM.MarziA.MunsterV.Functional assessment of"/>
  <result pre="SARS in the Greater Toronto AreaJAMA2003289280110.1001/jama.289.21.JOC3088512734147 38.TanE.L.OoiE.E.LinC.-Y.TanH.C.LingA.E.LimB.StantonL.W.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.20041058158610.3201/eid1004.03045815200845"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 40.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.In vitro antiviral activity"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 41.MartinezM.A.Compounds with"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 41.MartinezM.A.Compounds with therapeutic"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 41.MartinezM.A.Compounds with therapeutic potential"/>
  <result pre="2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 41.MartinezM.A.Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob. Agents Chemother.202010.1128/AAC.00399-20 42.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for"/>
  <result pre="2019 coronavirusAntimicrob. Agents Chemother.202010.1128/AAC.00399-20 42.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 43.LimJ.JeonS.ShinH.-Y.KimM.J.SeongY.M.LeeW.J.ChoeK.-W.KangY.M.LeeB.ParkS.-J.Case of the index patient who caused"/>
  <result pre="coronavirusAntimicrob. Agents Chemother.202010.1128/AAC.00399-20 42.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 43.LimJ.JeonS.ShinH.-Y.KimM.J.SeongY.M.LeeW.J.ChoeK.-W.KangY.M.LeeB.ParkS.-J.Case of the index patient who caused tertiary"/>
  <result pre="of the index patient who caused tertiary transmission of coronavirus" exact="disease" post="2019 in Korea: The application of lopinavir/ritonavir for the"/>
  <result pre="Korea: The application of lopinavir/ritonavir for the treatment of COVID-19" exact="pneumonia" post="monitored by quantitative RT-PCRJ. Korean Med Sci.202035e7910.3346/jkms.2020.35.e7932056407 44.DongL.HuS.GaoJ.Discovering drugs"/>
  <result pre="quantitative RT-PCRJ. Korean Med Sci.202035e7910.3346/jkms.2020.35.e7932056407 44.DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 45.HoffmannM.Kleine-WeberH.KrÃ¼gerN.MÃ¼llerM.DrostenC.PÃ¶hlmannS.A MullerM.The novel coronavirus 2019"/>
  <result pre="studyEng.202010.1016/j.eng.2020.03.007 47.FanH.-H.WangL.-Q.LiuW.-L.AnX.-P.LiuZ.-D.HeX.-Q.SongL.-H.TongY.-G.Repurposing of clinically approved drugs for treatment of coronavirus" exact="disease" post="2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus modelChin."/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.202061410.1038/s41421-019-0132-831934347 50.ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and hydroxychloroquine as available weapons"/>
  <result pre="molecule GS-5734 against Ebola virus in rhesus monkeysNature201653138138510.1038/nature1718026934220 54.AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.SmithE.C.CaseJ.B.FengJ.Y.JordanR.et al.Coronavirus" exact="Susceptibility to" post="the Antiviral Remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="Susceptibility to the Antiviral Remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading ExoribonucleasemBio20189e00221-1810.1128/mBio.00221-1829511076 55.TchesnokovE.P.FengJ.Y.PorterD.P.GotteM.Mechanism of inhibition of"/>
  <result pre="2020) 60.ShamH.L.KempfD.J.MollaA.MarshK.C.KumarG.N.ChenC.-M.KatiW.StewartK.LalR.HsuA.et al.ABT-378, a Highly potent inhibitor of the human" exact="immunodeficiency" post="virus proteaseAntimicrob. Agents Chemother.1998423218322410.1128/AAC.42.12.32189835517 61.LeonisG.CzyÅ¼nikowskaÅ».MegariotisG.ReisH.PapadopoulosM.G.Computational studies of darunavir into"/>
  <result pre="Chem. Inf. Model.2012521542155810.1021/ci300014z22587384 62.KawaseM.ShiratoK.Van Der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
  <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 63.RajamG.SampsonJ.CarloneG.M.AdesE.W.an augmented passive immune"/>
  <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 63.RajamG.SampsonJ.CarloneG.M.AdesE.W.an augmented passive immune therapy"/>
  <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 63.RajamG.SampsonJ.CarloneG.M.AdesE.W.an augmented passive immune therapy to"/>
  <result pre="entryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 63.RajamG.SampsonJ.CarloneG.M.AdesE.W.an augmented passive immune therapy to treat fulminant" exact="bacterial" post="infectionsRecent Patents Anti-Infective Drug DiscoveryBentham Science PublishersSharjah, UAE201015716710.2174/157489110791233496 64.MaranoG.VaglioS.PupellaS.FaccoG.CatalanoL.LiumbrunoG.M.GrazziniG.Convalescent"/>
  <result pre="coronavirus-specific human monoclonal antibodyEmerg. Microbes Infect.2020938238510.1080/22221751.2020.172906932065055 67.FuQ.SunJ.YanY.The functional aspects of" exact="bacterial" post="CRISPR-cas systems and interactions between phages and its bacterial"/>
  <result pre="of bacterial CRISPR-cas systems and interactions between phages and its" exact="bacterial" post="hostsâ€&quot;a reviewActa Microbiol. Sin.201555251257 Figure 1 The genomic organization"/>
  <result pre="the entry of the virus into the host cell, the" exact="viral" post="RNA is unveiled in the cytoplasm. ORF1a and ORF1ab"/>
  <result pre="by budding into the lumen of the endoplasmic reticulum (ER)â€&quot;Golgi" exact="intermediate" post="compartment. Virions are then released from the infected cell"/>
  <result pre="protocols [41] Remdesivir Antiviral drug (Nucleoside analogue) Interfering with the" exact="viral" post="replication Investigational antiviral, clinical trials are in progress [42]"/>
  <result pre="replication Investigational antiviral, clinical trials are in progress [42] Baricitinib" exact="Rheumatoid arthritis" post="(RA) drug, AP2-associated protein kinase 1 (AAK1) inhibitor Interfering"/>
  <result pre="Investigational antiviral, clinical trials are in progress [42] Baricitinib Rheumatoid" exact="arthritis" post="(RA) drug, AP2-associated protein kinase 1 (AAK1) inhibitor Interfering"/>
  <result pre="(RA) drug, AP2-associated protein kinase 1 (AAK1) inhibitor Interfering with" exact="viral" post="entry by inhibiting one of the endocytosis regulators FDA"/>
  <result pre="Camostat Mesylate Transmembrane protease, serine 2 (TMPRSS2) inhibitor Interfering with" exact="viral" post="entry Japan approved [46] Favipiravir Nucleoside analog Binds to"/>
  <result pre="entry Japan approved [46] Favipiravir Nucleoside analog Binds to the" exact="viral" post="RdRp and reduce its reproduction Investigational [47] Cepharanthie, Selamectin,"/>
  <result pre="activities Significantly reduced cytopathic effects of SARS-CoV-2, and decrease the" exact="viral" post="load Investigational [48] Ivermectin Anti-parasite Inhibits SARS-CoV-2 replication in"/>
 </snippets>
</snippetsTree>
